Table 3.
Frequency and rates of death reported to VAERS by recipients of mRNA COVID-19 vaccines, by sex and age group
|
Both mRNA vaccines (n=4471*) |
BNT162b2 vaccine (n=2086) |
mRNA-1273 vaccine (n=2385) |
||||
|---|---|---|---|---|---|---|
| n (%) | Reports per million doses administered† | n (%) | Reports per million doses administered† | n (%) | Reports per million doses administered† | |
| Sex | ||||||
| Female | 1906 (42·6%) | 12·2 | 918 (44·0%) | 10·6 | 988 (41·4%) | 14·2 |
| Male | 2485 (55·6%) | 18·5 | 1116 (53·5%) | 15·1 | 1369 (57·4%) | 22·6 |
| Unknown‡ | 80 (1·8%) | .. | 52 (2·5%) | .. | 28 (1·2%) | ..- |
| Age, years | ||||||
| 16–17 | 6 (0·1%) | 1·1 | 6 (0·3%) | 1·1 | .. | .. |
| 18–29 | 51 (1·1%) | 1·3 | 27 (1·3%) | 1·1 | 24 (1·0%) | 1·6 |
| 30–39 | 94 (2·1%) | 2·4 | 50 (2·4%) | 2·2 | 44 (1·8%) | 2·8 |
| 40–49 | 151 (3·4%) | 3·8 | 74 (3·5%) | 3·2 | 77 (3·2%) | 4·6 |
| 50–59 | 328 (7·3%) | 6·9 | 132 (6·3%) | 5·0 | 196 (8·2%) | 9·3 |
| 60–69 | 765 (17·1%) | 14·4 | 354 (17·0%) | 13·0 | 411 (17·2%) | 16·0 |
| 70–79 | 1117 (25·0%) | 28·5 | 496 (23·8%) | 25·9 | 621 (26·0%) | 31·0 |
| 80–89 | 1128 (25·2%) | 75·4 | 529 (25·4%) | 72·1 | 599 (25·1%) | 78·6 |
| ≥90 | 637 (14·2%) | 207·7 | 302 (14·5%) | 188·1 | 335 (14·0%) | 229·3 |
| Unknown‡ | 194 (4·3%) | .. | 116 (5·6%) | .. | 78 (3·3%) | .. |
Includes reports made and vaccines administered from Dec 14, 2020, to June 14, 2021. VAERS=Vaccine Adverse Event Reporting System.
*
Of 4496 deaths, 25 were excluded as they could not be confirmed or were duplicate reports upon review.
†
Doses of vaccine administered in the study period were used for denominators in each age group; does not include doses administered in Texas because data for Texas were reported to the US Centers for Disease Control and Prevention in aggregate.
‡
Reporting rates not shown for unknown categories because of unreliable dose denominators.